June 22, 2020 / 12:49 PM / 21 days ago

BRIEF-Onconova Therapeutics Announces The Initiation Of A Phase 1/2A Study Of Rigosertib Plus Nivolumab For The Treatment Of Kras+ Lung Adenocarcinoma

Onconova Therapeutics Inc:

* ONCONOVA THERAPEUTICS ANNOUNCES THE INITIATION OF A PHASE 1/2A STUDY OF RIGOSERTIB PLUS NIVOLUMAB FOR THE TREATMENT OF KRAS+ LUNG ADENOCARCINOMA Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below